ArticleTranslational oncology2026
Centrosome-related gene SPHK1 drives bladder cancer progression and therapeutic vulnerability.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCentrosome-related genes (CRGs) regulate cell division and genomic stability and may influence tumor progression, but their prognostic and functional roles in bladder cancer (BLCA) are not fully defined.
methodsWe curated 698 CRGs and identified 12 prognostic genes to construct a centrosome-related signature score (CRSS). The prognostic value of CRSS was evaluated in TCGA and GSE13507 cohorts. Functional enrichment, immune landscape, and drug sensitivity were analyzed through pathway analysis, ESTIMATE, and IC50 prediction. Machine learning and Mendelian randomization were used to identify the most promising CRGs. Furthermore, we performed single-cell RNA sequencing analysis to uncover the expression patterns of candidate CRGs. Expression and functional validation were performed using RT-qPCR, CCK-8, wound-healing assays, and immunohistochemistry.
resultsCRSS stratified patients into high- and low-risk groups with significant differences in overall survival. High-risk patients exhibited upregulated Aerobic glycolysis (AC), oxidative phosphorylation (OxPhos) and partial epithelial-mesenchymal transition (pEMT) pathways, higher immune/stromal scores, and distinct immune infiltration, including increased M0/M2 macrophages and decreased CD8⁺ T and follicular helper T cells. High-risk tumors showed altered sensitivity to multiple drugs, including AZD8186 and Staurosporine. Integrative analyses identified SPHK1 as a key candidate CRG. SPHK1 expression was associated with tumor grade, stage, poor survival, and the wound-healing molecular subtype. Functional assays showed that SPHK1 knockdown inhibited bladder cancer cell proliferation and migration. Immunohistochemistry further confirmed higher SPHK1 expression in tumors with more aggressive clinicopathological features.
conclusionsWe established a CRG-based model for BLCA and identified SPHK1 as a key gene associated with tumor progression and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.